La Jolla Institute for Allergy and Immunology

Epimmune Inc.

Cytel Corporation

Pharmexa Inc.

Alk-abello A/s

Genimmune N.v.

Ose Pharma International Sa

USA As Represented by Secretary of the Navy

Sandoz Gmbh

Sloan-kettering Institute for Cancer Research

Alk-abelló, Inc.

Epimunne Inc.

Biotech Synergy, Inc.

Idm Pharma, Inc.

Alessandro D Sette

John Sidney

Howard M Grey

Robert W Chesnut

Esteban Celis

Scott Southwood

Brian D Livingston

John D Fikes

Bjoern Peters

Ralph T Kubo

Federico C Gaeta

Mark Joseph Newman

Glenn Ishioka

Maria A Vitiello

Scott Douglas Power

Lilia Maria Babe

Yiyou Chen

Klaus Ley

Gitte Lund

Denise Marie Baker

Jason Greenbaum

Lars Harder Christensen

Claus Lundegaard

Lawrence M Deyoung

Manley T F Huang

Robert W Chestnut

Jeffrey L Alexander

David A Scheinberg

Carl F Ware

Michael Croft

Peter Sejer Andersen

Thomas S Arrhenius

Shahram Salek-Ardakani

Gary G Hermanson

Elissa Keogh

Michael Frank Powell

Denise L Doolan

Jeffery L Alexander

Sonia Sharma

Daniel John Carucci

Wybe Martin Kast

Lise Lund Mærkedahl

Peter Adler Würtzen

Sujan Shresta

Magdalini Moutaftsi

John C Sidney

Susanne Sønderkær

Peter Adler Wurtzen

Jens Brimnes

Thomas Stranzl

Glen Ishioka

W Martin Kast

Veronique Schulten

Helene Henmar

Shabnam Tangri

Cecilia Lindestam Arlehamn

Thomas Christian Mygind

Greg Seumois

Shashank Gupta

Cornelis Joseph Maria Melief

Pandurangan Vijayanand

Glenn Y Ishioka

Carla Oseroff

Lauren Yauch

Cecilia Arlehamm

Daniela Weiskopf

Monica Bocchia

Mark J Newman

Robert Chesnut

David H Brown

Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders.

Human ApoB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis

The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.

Antigens and T cell epitopes from cockroach and methods of making and using same

The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.

T cell epitopes from Cockroach and methods of making and using same

Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis

The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.

Peptide combinations and uses thereof for treating grass allergy

The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Epitopes from allergen proteins and methods and uses for immune response modulation

The present invention relates toproteins and peptides, and subsequences, portions or modifications thereof and methods and compounds comprising the same for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-immune response in a subject.

Antigens and epitopes derived from

The invention relates to novel immunogenic polypeptides identified in house dust mites and storage mites, which have the potential to be used in allergy immunotherapy, for diagnostic purposes, eventually via production of antibodies binding the polypeptide or for characterising allergen extracts of house dust mites and storage mites.

Immunogenic proteins and fragments thereof from allergenic mites

The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologs, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

Timothy grass allergens and methods and uses for immune response modulation

The invention relates to novel targets for immune response modulation, treatment of tuberculosis infection and epitopes of, or subsequences, portions or modifications thereof, and methods and compounds for treatment and prevention of tuberculosis infection.

Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of

Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8T cell response or an anti-DV CD4T cell response. Such peptides, nucleotide sequences and compositions can also be used for and in methods of vaccination/immunization of a subject against Dengue virus (DV) (e.g., to provide protection against DV infection and/or pathology), and for treatment of a subject in need thereof, for example, treatment of the subject for a Dengue virus (DV) infection or pathology.

Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof

The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.

Virus vaccination and treatment methods with OX40 agonist compositions

The invention relates to combinations of peptides or variants thereof derived from a portion of an amino sequence of a house dust mite allergen, e.g. the allergens Der p 1, Der f 1, Der p 2 and/or Der f 2. Such peptides comprise at least one T cell epitope and a significant high number of patients in a worldwide population will have HLA alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by a dust mite.

Peptide combinations and uses thereof in treating dust mite allergy

A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.

HLA-A2 tumor associated antigen peptides and compositions

Growing community of inventors

La Jolla, CA, United States of America

Alessandro D Sette